MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences Long-Term Debt 2011-2026 | GILD
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 B | 24.9 B | 23.2 B | 23 B | 25.2 B | 28.6 B | 22.1 B | 24.6 B | 30.8 B | 26.3 B | 21.2 B | 11.9 B | 3.94 B | 7.05 B | 7.61 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.8 B | 3.94 B | 20.2 B |
Quarterly Long-Term Debt Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.1 B | 22.1 B | 22.1 B | 24.9 B | 21.4 B | 21.5 B | 21.5 B | 23.2 B | 23.2 B | 21.2 B | 23 B | 23 B | 23 B | 25.2 B | 25.2 B | 25.2 B | 25.2 B | 27.9 B | 27.9 B | 28.6 B | 28.6 B | 28.6 B | 28.6 B | 22.1 B | 22.1 B | 22.1 B | 22.1 B | 24.6 B | 24.6 B | 24.6 B | 24.6 B | 30.8 B | 30.8 B | 30.8 B | 30.8 B | 26.3 B | 26.3 B | 26.3 B | 26.3 B | 21.1 B | 21.1 B | 21.1 B | 21.1 B | 11.9 B | 11.9 B | 11.9 B | 11.9 B | 3.94 B | 3.94 B | 3.94 B | 3.94 B | 7.05 B | 7.05 B | 7.05 B | 7.05 B | 7.61 B | 7.61 B | 7.61 B | 7.61 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30.8 B | 3.94 B | 20.1 B |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M |  USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Aquestive Therapeutics
AQST
|
45 M | $ 4.2 | 2.57 % | $ 364 M | USA |
 |
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | USA |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
59.9 K | $ 3.35 | 0.72 % | $ 8.06 B |  Australia |
 |
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
275 K | $ 1.25 | 0.1 % | $ 1.85 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
756 K | $ 61.64 | -1.57 % | $ 11.7 B | USA |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Atea Pharmaceuticals
AVIR
|
842 K | $ 4.59 | -1.4 % | $ 387 M | USA |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
1.88 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Capricor Therapeutics
CAPR
|
1.49 M | $ 28.36 | 1.61 % | $ 759 M | USA |
 |
CASI Pharmaceuticals
CASI
|
1.1 M | $ 0.36 | -54.61 % | $ 49 M | USA |
 |
Axsome Therapeutics
AXSM
|
118 M | $ 164.67 | -3.11 % | $ 8.19 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
60.3 M | - | -11.76 % | $ 5.79 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
78.5 M | - | -4.8 % | $ 255 M | USA |
 |
Catalyst Biosciences
CBIO
|
199 K | $ 12.11 | -4.27 % | $ 797 M | USA |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
166 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
6.29 B | $ 190.86 | -2.19 % | $ 28 B | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
25.7 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
1.52 M | - | 0.59 % | $ 63 K | USA |
 |
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
22.1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Cellectis S.A.
CLLS
|
28.8 M | $ 4.17 | 4.77 % | $ 116 M | France |
 |
Aridis Pharmaceuticals
ARDS
|
1.29 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
231 M | $ 111.05 | 0.14 % | $ 27.2 B | Germany |